Please login to the form below

Not currently logged in
Email:
Password:

Reata

This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... Reata collected historical eGFR data for

Latest news

  • Abbott agrees $400m chronic disease deal with Reata

    The pharma company will make a one-off payment of $400m to Texas, US-based Reata Pharmaceuticals for its second-generation oral antioxidant inflammation modulators (AIMs). ... For these conditions, Abbott will take 70 per cent of costs and profits, while

  • Regional plans

    A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition.  . 461. Reata/Abbott. Bardoxolone for chronic

  • Abbott signs kidney drug deal

    Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney disease. ... Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney

  • Advancing acquisitions

    P1 . 334. Reata Pharma/Kyowa Hakko . Bardoxolone in chronic kidney disease. P2a .

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics